{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:41:28Z","timestamp":1777030888763,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.chest.2016.12.004","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T15:16:44Z","timestamp":1482160604000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Malignant Mesothelioma Biomarkers"],"prefix":"10.1016","volume":"152","author":[{"given":"Jenette","family":"Creaney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce W.S.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.chest.2016.12.004_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/resp.12517","article-title":"Asbestos in Asia","volume":"20","author":"Leong","year":"2015","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.chest.2016.12.004_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1753465816628800","article-title":"Malignant pleural mesothelioma: an update on diagnosis and treatment options","volume":"10","author":"Kondola","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.chest.2016.12.004_bib3","series-title":"Genomic and Personalized Medicine","first-page":"263","article-title":"Validation of candidate protein biomarkers","author":"Pavlou","year":"2013"},{"issue":"11","key":"10.1016\/j.chest.2016.12.004_bib4","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.chest.2016.12.004_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-213X-3-2","article-title":"Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells","volume":"3","author":"Prieve","year":"2003","journal-title":"BMC Dev Biol"},{"issue":"3","key":"10.1016\/j.chest.2016.12.004_bib6","doi-asserted-by":"crossref","first-page":"e0122462","DOI":"10.1371\/journal.pone.0122462","article-title":"Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line","volume":"10","author":"Hollevoet","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.chest.2016.12.004_bib7","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","article-title":"Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma","volume":"96","author":"Scholler","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9396","key":"10.1016\/j.chest.2016.12.004_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.chest.2016.12.004_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.chest.2016.12.004_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/17530059.1.1.137","article-title":"MESOMARK(\u00ae) in\u00a0vitro diagnostic test for mesothelioma","volume":"1","author":"Li","year":"2007","journal-title":"Expert Opin Med Diagn"},{"issue":"1","key":"10.1016\/j.chest.2016.12.004_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1373\/clinchem.2012.184614","article-title":"The long journey of cancer biomarkers from the bench to the clinic","volume":"59","author":"Pavlou","year":"2013","journal-title":"Clin Chem"},{"issue":"13","key":"10.1016\/j.chest.2016.12.004_bib12","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.chest.2016.12.004_bib13","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schroder","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2016.12.004_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.lungcan.2011.01.011","article-title":"Mesothelin and kidney function\u2013analysis of relationship and implications for mesothelioma screening","volume":"73","author":"Boudville","year":"2011","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.chest.2016.12.004_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/rccm.200811-1729OC","article-title":"Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions","volume":"180","author":"Davies","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2016.12.004_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1183\/09031936.00148211","article-title":"A\u00a0prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions","volume":"41","author":"Hooper","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2016.12.004_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/07357907.2012.749265","article-title":"Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology","volume":"31","author":"Canessa","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.chest.2016.12.004_bib18","doi-asserted-by":"crossref","first-page":"413946","DOI":"10.1155\/2014\/413946","article-title":"Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma","volume":"2014","author":"Creaney","year":"2014","journal-title":"Dis Markers"},{"issue":"7","key":"10.1016\/j.chest.2016.12.004_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Creaney","year":"2007","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.chest.2016.12.004_bib20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment","volume":"179","author":"Grigoriu","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"10.1016\/j.chest.2016.12.004_bib21","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma","volume":"28","author":"Wheatley-Price","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.chest.2016.12.004_bib22","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.chest.2016.12.004_bib23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.chest.2016.12.004_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A\u00a0phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"issue":"21","key":"10.1016\/j.chest.2016.12.004_bib25","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.chest.2016.12.004_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/bjc.2015.62","article-title":"The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication","volume":"112","author":"Hooper","year":"2015","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.chest.2016.12.004_bib27","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1055-9965.EPI-10-0346","article-title":"Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma","volume":"19","author":"Creaney","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.chest.2016.12.004_bib28","series-title":"Malignant Pleural Mesothelioma: Present Status and Future Directions","first-page":"251","article-title":"Serum biomarkers in malignant pleural mesothelioma","author":"Dick","year":"2015"},{"issue":"8","key":"10.1016\/j.chest.2016.12.004_bib29","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200802-258OC","article-title":"Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study","volume":"178","author":"Park","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2016.12.004_bib30","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/JTO.0b013e31820db377","article-title":"Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.chest.2016.12.004_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00204-010-0580-2","article-title":"Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos","volume":"85","author":"Gube","year":"2011","journal-title":"Arch Toxicol"},{"issue":"2","key":"10.1016\/j.chest.2016.12.004_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00420-013-0853-1","article-title":"Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers","volume":"87","author":"Felten","year":"2014","journal-title":"Int Arch Occup Environ Health"},{"issue":"1","key":"10.1016\/j.chest.2016.12.004_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000355687","article-title":"Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos","volume":"86","author":"Filiberti","year":"2014","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.chest.2016.12.004_bib34","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.chest.2016.12.004_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12014-016-9103-3","article-title":"ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms","volume":"13","author":"Morre","year":"2016","journal-title":"Clin Proteomics"},{"issue":"6","key":"10.1016\/j.chest.2016.12.004_bib36","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.chest.2016.12.004_bib37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"261","key":"10.1016\/j.chest.2016.12.004_bib38","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T\u00a0cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"issue":"208","key":"10.1016\/j.chest.2016.12.004_bib39","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.chest.2016.12.004_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/1097-0142(19890701)64:1<68::AID-CNCR2820640112>3.0.CO;2-I","article-title":"A\u00a0longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease","volume":"64","author":"Dahl","year":"1989","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.chest.2016.12.004_bib41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","article-title":"Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma","volume":"82","author":"Creaney","year":"2013","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.chest.2016.12.004_bib42","doi-asserted-by":"crossref","first-page":"e72030","DOI":"10.1371\/journal.pone.0072030","article-title":"Hyaluronan and N-ERC\/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma","volume":"8","author":"Mundt","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.chest.2016.12.004_bib43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/dc.23271","volume":"43","author":"Hjerpe","year":"2015","journal-title":"Diagn Cytopathol"},{"issue":"2","key":"10.1016\/j.chest.2016.12.004_bib44","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor","volume":"141","author":"Hollevoet","year":"2012","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2016.12.004_bib45","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.chest.2016.12.004_bib46","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chest.2016.12.004_bib47","doi-asserted-by":"crossref","first-page":"e72458","DOI":"10.1371\/journal.pone.0072458","article-title":"Identification of novel autoantibodies for detection of malignant mesothelioma","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.chest.2016.12.004_bib48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.chest.2016.12.004_bib49","doi-asserted-by":"crossref","first-page":"e114483","DOI":"10.1371\/journal.pone.0114483","article-title":"Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921662593X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921662593X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:33:32Z","timestamp":1757921612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236921662593X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S001236921662593X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2016.12.004","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant Mesothelioma Biomarkers","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}